142 related articles for article (PubMed ID: 22642189)
1. Specificity of binding with matrix metalloproteinases.
Gupta SP; Patil VM
Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
[TBL] [Abstract][Full Text] [Related]
2. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
[TBL] [Abstract][Full Text] [Related]
3. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
[TBL] [Abstract][Full Text] [Related]
4. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses.
Eckhard U; Huesgen PF; Schilling O; Bellac CL; Butler GS; Cox JH; Dufour A; Goebeler V; Kappelhoff R; Keller UAD; Klein T; Lange PF; Marino G; Morrison CJ; Prudova A; Rodriguez D; Starr AE; Wang Y; Overall CM
Matrix Biol; 2016 Jan; 49():37-60. PubMed ID: 26407638
[TBL] [Abstract][Full Text] [Related]
5. Similarity of binding sites of human matrix metalloproteinases.
Lukacova V; Zhang Y; Mackov M; Baricic P; Raha S; Calvo JA; Balaz S
J Biol Chem; 2004 Apr; 279(14):14194-200. PubMed ID: 14732707
[TBL] [Abstract][Full Text] [Related]
6. Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
Baidya SK; Banerjee S; Adhikari N; Jha T
J Med Chem; 2022 Aug; 65(16):10709-10754. PubMed ID: 35969157
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
8. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
[TBL] [Abstract][Full Text] [Related]
9. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1.
Welch AR; Holman CM; Huber M; Brenner MC; Browner MF; Van Wart HE
Biochemistry; 1996 Aug; 35(31):10103-9. PubMed ID: 8756473
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
11. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.
Fabre B; Ramos A; de Pascual-Teresa B
J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401
[TBL] [Abstract][Full Text] [Related]
12. Subsite specificity (S3, S2, S1', S2' and S3') of oligopeptidase B from Trypanosoma cruzi and Trypanosoma brucei using fluorescent quenched peptides: comparative study and identification of specific carboxypeptidase activity.
Hemerly JP; Oliveira V; Del Nery E; Morty RE; Andrews NW; Juliano MA; Juliano L
Biochem J; 2003 Aug; 373(Pt 3):933-9. PubMed ID: 12737623
[TBL] [Abstract][Full Text] [Related]
13. Contribution of lysine 60f to S1' specificity of thrombin.
Rezaie AR; Olson ST
Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
Pirard B; Matter H
J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases: fold and function of their catalytic domains.
Tallant C; Marrero A; Gomis-Rüth FX
Biochim Biophys Acta; 2010 Jan; 1803(1):20-8. PubMed ID: 19374923
[TBL] [Abstract][Full Text] [Related]
16. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure.
Lang R; Kocourek A; Braun M; Tschesche H; Huber R; Bode W; Maskos K
J Mol Biol; 2001 Sep; 312(4):731-42. PubMed ID: 11575928
[TBL] [Abstract][Full Text] [Related]
17. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
18. Analysis of X-ray structures of matrix metalloproteinases via chaotic map clustering.
Giangreco I; Nicolotti O; Carotti A; De Carlo F; Gargano G; Bellotti R
BMC Bioinformatics; 2010 Oct; 11():500. PubMed ID: 20932281
[TBL] [Abstract][Full Text] [Related]
19. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.
Terp GE; Cruciani G; Christensen IT; Jørgensen FS
J Med Chem; 2002 Jun; 45(13):2675-84. PubMed ID: 12061871
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
